Overweight and obesity versus concentrations of VEGF-A, sVEGFR-1, and sVEGFR-2 in plasma of patients with lower limb chronic ischemia

ObjectiveBeing overweight or obese comprises a significant risk factor for atherosclerosis. Fat tissue also generates factors stimulating angiogenesis, the process by which new blood vessels form. The purpose of this paper is to assess concentrations of the vascular endothelial growth factor A (VEGF-A) and its soluble type-1 and type-2 receptors (sVEGFR-1 and sVEGFR-2) in plasma of patients with peripheral arterial disease (PAD) depending on the level of nutrition according to body mass index (BMI).MethodsThe study group included patients suffering from symptomatic PAD (n=46) in Fontaine classes IIa–IV without any history of neoplastic disease and who have a normal BMI (n=15), are overweight (n=21) or are obese (n=10). The control group (n=30) consisted of healthy non-smoking volunteers who were neither overweight nor obese. Venous blood plasma samples were collected from both groups at rest in the morning to determine plasma concentrations of VEGF-A, sVEGFR-1, and sVEGFR-2 using the enzymelinked immunosorbent assay (ELISA) method.ResultsThe group of patients with PAD co-existent with being overweight or obese tended to have higher mean concentration levels of VEGF-A and sVEGFR-2 when compared with patients suffering from PAD with normal BMI. A statistically significant positive correlation was obtained between BMI and average plasma concentrations of sVEGFR-2 (R=0.37, P=0.0103). However, no significant correlation was noticed between BMI and VEGF-A or sVEGFR-1 concentrations.ConclusionsA positive correlation determined between the level of antiangiogenic factor and BMI value may be indicative of the linearly growing prevalence of some antiangiogenic factors in patients with metabolic disorders, which may be one of numerous factors contributing to incomplete efficiency of collateral circulation development in patients with PAD.中文概要目 的研究外周动脉疾病(PAD) 患者血浆中血管内皮 生长因子A(VEGF-A) 和它的可溶性1 型和2 型受体(sVEGFR-1 和sVEGFR-2) 的浓度与营 养水平的关系, 同时根据身体质量指数(BMI) 来评估营养水平。创新点将血管生成与超重和肥胖及下肢局部缺血联系起 来, 并根据BMI 评估了它们之间的关系。方 法研究组包括46 名Fontaine 等级IIa 至IV 且没有 任何肿瘤疾病史的PAD 症状患者, 其中15 名 BMI 正常, 21 名超重, 10 名肥胖。对照组由30 名不超重且不肥胖的健康非吸烟志愿者组成。试 验在上午休息时间采集两组静脉血的血浆标本, 用酶联免疫吸附(ELISA) 方法确定血浆中的 VEGF-A、sVEGFR-1 和sVEGFR-2 浓度。结 论如果PAD 患者同时伴随着超重或者肥胖, 会影 响血管再生的过程。sVEGFR-2 水平和BMI 值之 间有正相关关系, 这说明代谢紊乱患者中的一些 抗血管生成因子患病率的线性增长的原因, 同时 这可能是导致PAD 患者侧支循环发展效率不完 全的众多因素之一。

[1]  K. Suppan,et al.  Selected angiogenic factors in plasma of patients with lower limb symptomatic peripheral arterial disease: preliminary report. , 2015, International angiology : a journal of the International Union of Angiology.

[2]  K. Suppan,et al.  Impact of type 2 diabetes on the plasma levels of vascular endothelial growth factor and its soluble receptors type 1 and type 2 in patients with peripheral arterial disease , 2015, Journal of Zhejiang University-SCIENCE B.

[3]  K. Suppan,et al.  C0238: Plasma VEGF-A/SVEGFR-1 Ratio as a Potential Ischemic Marker in Patients with Symptomatic Peripheral Arterial Disease – Preliminary Report , 2014 .

[4]  Tao Jiang,et al.  Expression and characterization of a soluble VEGF receptor 2 protein , 2014, Cell & Bioscience.

[5]  P. Barć,et al.  Transplantation of autologous bone marrow mononuclear cells with VEGF gene improves diabetic critical limb ischaemia. , 2013, Endokrynologia Polska.

[6]  Raimund Erbel,et al.  [2011 ESC guidelines on the diagnosis and treatment of peripheral artery diseases]. , 2012, Revue medicale de Liege.

[7]  M. Fujita,et al.  Distinct Characteristics of Circulating Vascular Endothelial Growth Factor-A and C Levels in Human Subjects , 2011, PloS one.

[8]  B. Kos-Kudła,et al.  [Vascular endothelial growth factor (VEGF) in endocrinology and oncology]. , 2011, Endokrynologia Polska.

[9]  K. Oltmanns,et al.  Evidence for a Relationship between VEGF and BMI Independent of Insulin Sensitivity by Glucose Clamp Procedure in a Homogenous Group Healthy Young Men , 2010, PloS one.

[10]  D. Ahmadvand,et al.  Inhibition of Angiogenesis by Recombinant VEGF Receptor Fragments , 2010 .

[11]  E. Geissler,et al.  VEGF: a surrogate marker for peripheral vascular disease. , 2010, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[12]  B. Paulweber,et al.  Are plasma VEGF and its soluble receptor sFlt-1 atherogenic risk factors? Cross-sectional data from the SAPHIR study. , 2009, Atherosclerosis.

[13]  R. G. Mitchell,et al.  Plasma levels of soluble Tie2 and vascular endothelial growth factor distinguish critical limb ischemia from intermittent claudication in patients with peripheral arterial disease. , 2008, Journal of the American College of Cardiology.

[14]  H. Lijnen.  Angiogenesis and obesity. , 2008, Cardiovascular research.

[15]  A. Mizia-Malarz,et al.  [Angiogenesis in the chronic inflammatory diseases and malignancies]. , 2008, Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego.

[16]  K. Sworczak,et al.  [Hemostatic disturbances in obesity]. , 2007, Wiadomosci lekarskie.

[17]  P. Sucharda,et al.  Angiogenic factors are elevated in overweight and obese individuals , 2005, International Journal of Obesity.

[18]  P. Kurjata,et al.  [Incidence of overweight and obesity in women and men between the ages of 20-74. Results of the WOBASZ program]. , 2005, Kardiologia polska.

[19]  星本 さおり.  Elevated serum vascular endothelial growth factor is associated with visceral fat accumulation in human obese subjects , 2005 .

[20]  H. Jerczyńska,et al.  [Vascular endothelial growth factor--structure and functions]. , 2005, Postepy biochemii.

[21]  B. Kou,et al.  In vivo inhibition of tumor angiogenesis by a soluble VEGFR-2 fragment. , 2004, Experimental and molecular pathology.

[22]  H. Bujo,et al.  Elevated serum vascular endothelial growth factor is associated with visceral fat accumulation in human obese subjects , 2003, Diabetologia.

[23]  R. Considine,et al.  Obesity is associated with increased levels of circulating hepatocyte growth factor. , 2003, Journal of the American College of Cardiology.

[24]  M. Małecki,et al.  The significance of vascular endothelial growth factor in the neoangiogenesis process. The role of hypoxia in the endothelial cells proliferation process and in the formation of collateral circulation , 2003 .

[25]  R. Busse,et al.  Leptin, the product of Ob gene, promotes angiogenesis. , 1998, Circulation research.

[26]  Takayuki Asahara,et al.  Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb , 1996, The Lancet.